South Dakota Investment Council Lowers Stake in Edwards Lifesciences Corporation $EW

South Dakota Investment Council reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 28.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,105 shares of the medical research company’s stock after selling 48,952 shares during the period. South Dakota Investment Council’s holdings in Edwards Lifesciences were worth $9,496,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $266,000. Arkadios Wealth Advisors acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $300,000. Assetmark Inc. raised its position in Edwards Lifesciences by 344.7% in the second quarter. Assetmark Inc. now owns 2,735 shares of the medical research company’s stock valued at $214,000 after purchasing an additional 2,120 shares during the period. Burney Co. acquired a new position in shares of Edwards Lifesciences during the second quarter worth about $2,857,000. Finally, Prosperity Consulting Group LLC boosted its position in shares of Edwards Lifesciences by 3.2% in the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after buying an additional 132 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on EW. Evercore reiterated an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $96.14.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 79,144 shares of company stock worth $6,685,688. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Down 2.2%

NYSE EW opened at $85.30 on Wednesday. The company’s fifty day moving average price is $82.74 and its two-hundred day moving average price is $81.39. The company has a market capitalization of $49.54 billion, a price-to-earnings ratio of 46.61, a price-to-earnings-growth ratio of 2.27 and a beta of 0.93. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.